Based on 4 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is C$14.82 with a high forecast of C$15.86 and a low forecast of C$12.98. The average price target represents a -3.80% change from the last price of C$15.41.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"C$11","16":"C$16","12.25":"C$12.25","13.5":"C$13.5","14.75":"C$14.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.86233,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$15.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.8240684,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$14.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.97827,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$12.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,12.25,13.5,14.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,15.444794615384616,15.47958923076923,15.514383846153846,15.549178461538462,15.583973076923076,15.618767692307692,15.653562307692308,15.688356923076924,15.723151538461538,15.757946153846154,15.79274076923077,15.827535384615384,{"y":15.86233,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,15.364928338461539,15.319856676923077,15.274785015384616,15.229713353846154,15.184641692307693,15.139570030769232,15.094498369230768,15.049426707692307,15.004355046153846,14.959283384615384,14.914211723076923,14.869140061538461,{"y":14.8240684,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,15.222943846153846,15.035887692307693,14.848831538461539,14.661775384615385,14.474719230769232,14.287663076923078,14.100606923076924,13.913550769230769,13.726494615384615,13.539438461538461,13.352382307692308,13.165326153846154,{"y":12.97827,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.41,"date":1703203200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetC$15.86

Average Price TargetC$14.82

Lowest Price TargetC$12.98

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Reiterated

11/19/24

Reiterated

11/18/24

Reiterated

11/11/24

Assigned

11/10/24

xxxxxxxxxxxxx

Ed Arce

H.C. Wainwright

C$18.75

Buy

21.65%

Upside

Reiterated

09/05/24

Buy Rating Affirmed for Aurinia Pharmaceuticals on AUR200's Clinical and Financial Promise

Maury Raycroft

Jefferies

C$12.98→C$8.65

Hold

-43.85%

Downside

Reiterated

05/02/24

Aurinia Pharmaceuticals (AUPH) PT Lowered to $6 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $6.00 (from $9.00) while maintaining a Hold rating.

Olivia Brayer

Cantor Fitzgerald

C$17.3→C$14.42

Buy

-6.42%

Downside

Reiterated

02/23/24

Aurinia Pharmaceuticals (AUPH) PT Lowered to $10 at Cantor FitzgeraldCantor Fitzgerald analyst Olivia Brayer lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $10.00 (from $12.00) while maintaining a Overweight rating.

Best Analysts Covering Aurinia Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy GB:0UJF and Sell After:

1 Month

xxx

Success Rate

20/32 ratings generated profit

Average Return

+11.85%

assigned a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +11.85% per trade.

3 Months

xxx

Success Rate

10/21 ratings generated profit

Average Return

+19.07%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of +19.07% per trade.

1 Year

David Martin PhDBloom Burton

Success Rate

13/21 ratings generated profit

Average Return

+33.09%

reiterated a buy rating last month

Copying David Martin PhD's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +33.09% per trade.

2 Years

xxx

Success Rate

12/21 ratings generated profit

Average Return

+37.12%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +37.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0UJF Analyst Recommendation Trends

Rating

Mar 24

May 24

Aug 24

Sep 24

Nov 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0UJF has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0UJF average Analyst price target in the past 3 months is C$14.82.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0UJF Financial Forecast

0UJF Earnings Forecast

Next quarter’s earnings estimate for 0UJF is C$0.02 with a range of -C$0.13 to C$0.23. The previous quarter’s EPS was C$0.14. 0UJF beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.82% of the time in the same period. In the last calendar year 0UJF has Outperformed its overall industry.

0UJF Sales Forecast

Next quarter’s sales forecast for 0UJF is C$86.05M with a range of C$82.67M to C$87.05M. The previous quarter’s sales results were C$97.01M. 0UJF beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.21% of the time in the same period. In the last calendar year 0UJF has Outperformed its overall industry.

0UJF Stock Forecast FAQ

What is GB:0UJF’s average 12-month price target, according to analysts?

Based on analyst ratings, Aurinia Pharmaceuticals’s 12-month average price target is C$14.82.

What is GB:0UJF’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0UJF, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Aurinia Pharmaceuticals a Buy, Sell or Hold?

Aurinia Pharmaceuticals has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Aurinia Pharmaceuticals’s share price target?

The average share price target for Aurinia Pharmaceuticals is C$14.82. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is C$15.86 ,and the lowest forecast is C$12.98. The average share price target represents -3.80% Decrease from the current price of C$15.41.

What do analysts say about Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Aurinia Pharmaceuticals?

To buy shares of GB:0UJF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Aurinia Pharmaceuticals (0UJF) Share Forecast & Price Target

0UJF Analyst Ratings

0UJF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aurinia Pharmaceuticals

0UJF Analyst Recommendation Trends

0UJF Financial Forecast

0UJF Earnings Forecast

0UJF Sales Forecast

0UJF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts